Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impendia: Glucose-Sparing PD in Diabetic ESRD
NCT00567398Phase 3Completed
- Sponsor
- Vanttive
- Start
- Apr 2008
- Primary completion
- Jul 2011
- Modality
- Polymer-based Nanoparticles, Device-based Delivery
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of Physioneal, icodextrin and Nutrineal in end stage renal disease (ESRD) (2 arms), sponsored by Vanttive. Primary endpoint: Change From the Baseline Value in HbA1c at 6 months. Started Apr 2008; status: completed.
02
Drugs
PhysionealicodextrinNutrineal
03
Conditions
end stage renal disease (ESRD)
Beyond the preview
Go deeper on NCT00567398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00567398.